Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB

Acrivon Therapeutics acquired ACR-525, a Phase 2-ready oral JAK1 inhibitor, and a PKCθ inhibitor preclinical program from Aqilion AB for undisclosed cash consideration. The acquisition establishes immunology and inflammation as a strategic pillar alongside oncology, with eosinophilic esophagitis targeted as the first indication. Acrivon's AP3 platform profiling characterized ACR-525 as a highly selective, potentially best-in-class JAK1 inhibitor with broad potential in IBD and other autoimmune disorders.